Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. S-9780
1. 95153-31-4
2. Perindoprilate
3. Perindoprilato
4. Perindoprilatum
5. S-9780
6. Perindopril Related Compound B
7. Perindopril Diacid Form
8. 2uv6znq92k
9. (2s,3as,7as)-1-((s)-2-(((s)-1-carboxybutyl)amino)propanoyl)octahydro-1h-indole-2-carboxylic Acid
10. (2s,3as,7as)-1-((s)-n-((s)-1-carboxybutyl)alanyl)hexahydro-2-indolinecarboxylic Acid
11. S 9780
12. Perindoprilate [french]
13. Perindoprilatum [latin]
14. Perindoprilato [spanish]
15. (2s,3as,7as)-1-(((s)-1-carboxybutyl)-l-alanyl)octahydro-1h-indole-2-carboxylic Acid
16. Perindoprilat [inn:ban]
17. Unii-2uv6znq92k
18. Brn 4207072
19. Perondropilat
20. Perondroprilat
21. Perindoprilat [inn]
22. Schembl564053
23. Gtpl6373
24. Chembl1201368
25. Dtxsid90869249
26. Chebi:132041
27. Hy-b1433
28. Zinc4217270
29. Perindopril Diacid Form [mi]
30. Akos026750118
31. Ccg-213925
32. Db14213
33. Ncgc00389603-01
34. (2s,3as,7as)-1-[(2s)-2-[[(1s)-1-carboxybutyl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic Acid
35. (2s,3as,7as)-1-[(2s)-2-[[(2s)-1-hydroxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic Acid
36. 1h-indole-2-carboxylic Acid, Octahydro-1-(2-((1-carboxybutyl)amino)-1-oxopropyl)-, (2s-(1(r*(r*)),2-alpha,3a-beta,7a-beta))-
37. Cs-0013140
38. C21517
39. Perindopril Related Compound B [usp-rs]
40. Ab01563365_01
41. 153p314
42. A1-06488
43. Q27088302
44. Perindopril Tert-butylamine Impurity B [ep Impurity]
45. Discontinued. Please See P287531 Or P287535 Or P287585.
46. N-{(2s)-1-[(2s,3as,7as)-2-carboxyoctahydro-1h-indol-1-yl]-1-oxopropan-2-yl}-l-norvaline
47. (2s,3as,7as)-1-((s)-2-(((s)-1-carboxybutyl)amino)propanoyl)octahydro-1h-indole-2-carboxylicacid
48. (2s,3as,7as)-1-[(2s)-2-[[(1s)-1-carboxybutyl]amino]-1-oxopropyl]octahydro-1h-indole-2-carboxylic Acid
49. (2s,3as,7as)-1-[(2s)-2-[[(2s)-1-hydroxy-1-oxopentan-2-yl]amino] Propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic Acid
50. (2s,3as,7as)-1-[(2s)-2-{[(1s)-1-carboxybutyl]amino}propanoyl]octahydro-1h-indole-2-carboxylic Acid
51. (2s,3as,7as)-1-[(2s)-2-{[(1s)-1-carboxybutyl]amino}propanoyl]octahydro-1h-indole-2-carboxylic Acid (non-preferred Name)
52. [2s-[1[r*(r*)],2alpha,3abeta,7abeta]]-1-[2-[(1-carboxybutyl)amino]-1-oxopropyl]octahydro-1h-indole-2-carboxylic Acid
53. X94
Molecular Weight | 340.4 g/mol |
---|---|
Molecular Formula | C17H28N2O5 |
XLogP3 | 0.2 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 7 |
Exact Mass | 340.19982200 g/mol |
Monoisotopic Mass | 340.19982200 g/mol |
Topological Polar Surface Area | 107 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 495 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 5 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Angiotensin-Converting Enzyme Inhibitors
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (See all compounds classified as Angiotensin-Converting Enzyme Inhibitors.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
ANALYTICAL
ABOUT THIS PAGE
A Perindoprilate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Perindoprilate, including repackagers and relabelers. The FDA regulates Perindoprilate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Perindoprilate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Perindoprilate supplier is an individual or a company that provides Perindoprilate active pharmaceutical ingredient (API) or Perindoprilate finished formulations upon request. The Perindoprilate suppliers may include Perindoprilate API manufacturers, exporters, distributors and traders.
Perindoprilate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Perindoprilate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Perindoprilate GMP manufacturer or Perindoprilate GMP API supplier for your needs.
A Perindoprilate CoA (Certificate of Analysis) is a formal document that attests to Perindoprilate's compliance with Perindoprilate specifications and serves as a tool for batch-level quality control.
Perindoprilate CoA mostly includes findings from lab analyses of a specific batch. For each Perindoprilate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Perindoprilate may be tested according to a variety of international standards, such as European Pharmacopoeia (Perindoprilate EP), Perindoprilate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Perindoprilate USP).
LOOKING FOR A SUPPLIER?